Bicocca Open Archive

Logo unimib boa
CAZZANIGA, MARINA ELENA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.501
AS - Asia 5.696
EU - Europa 4.981
SA - Sud America 921
AF - Africa 91
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 7
Totale 20.204
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.330
SG - Singapore 2.178
IT - Italia 1.423
CN - Cina 1.138
HK - Hong Kong 1.073
RU - Federazione Russa 911
BR - Brasile 743
DE - Germania 742
VN - Vietnam 632
IE - Irlanda 503
SE - Svezia 495
GB - Regno Unito 204
ID - Indonesia 169
UA - Ucraina 142
IN - India 116
AT - Austria 113
CA - Canada 108
FI - Finlandia 100
KR - Corea 93
FR - Francia 81
AR - Argentina 76
NL - Olanda 66
DK - Danimarca 53
BD - Bangladesh 47
TR - Turchia 45
MX - Messico 43
ZA - Sudafrica 43
ES - Italia 39
JP - Giappone 38
IQ - Iraq 33
EC - Ecuador 28
PL - Polonia 26
PK - Pakistan 23
CO - Colombia 20
LT - Lituania 16
UZ - Uzbekistan 16
CL - Cile 15
VE - Venezuela 15
BE - Belgio 14
PY - Paraguay 13
KE - Kenya 12
PS - Palestinian Territory 11
MA - Marocco 10
SA - Arabia Saudita 10
IR - Iran 9
JO - Giordania 8
RO - Romania 8
AE - Emirati Arabi Uniti 7
AL - Albania 7
CH - Svizzera 7
CZ - Repubblica Ceca 6
KZ - Kazakistan 6
NP - Nepal 6
UY - Uruguay 6
JM - Giamaica 5
SC - Seychelles 5
TN - Tunisia 5
AM - Armenia 4
AU - Australia 4
BG - Bulgaria 4
CR - Costa Rica 4
EG - Egitto 4
EU - Europa 4
IL - Israele 4
OM - Oman 4
PH - Filippine 4
SK - Slovacchia (Repubblica Slovacca) 4
TH - Thailandia 4
AZ - Azerbaigian 3
BO - Bolivia 3
HN - Honduras 3
TW - Taiwan 3
A1 - Anonimo 2
BH - Bahrain 2
BY - Bielorussia 2
DO - Repubblica Dominicana 2
DZ - Algeria 2
ET - Etiopia 2
LV - Lettonia 2
MD - Moldavia 2
MT - Malta 2
MU - Mauritius 2
MY - Malesia 2
NZ - Nuova Zelanda 2
PA - Panama 2
PE - Perù 2
PT - Portogallo 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BA - Bosnia-Erzegovina 1
BF - Burkina Faso 1
BW - Botswana 1
CY - Cipro 1
DM - Dominica 1
GA - Gabon 1
GR - Grecia 1
GT - Guatemala 1
HU - Ungheria 1
KG - Kirghizistan 1
KH - Cambogia 1
Totale 20.191
Salva come PNG Salva come JPEG
Città #
Ann Arbor 1.733
Singapore 1.381
Hong Kong 1.067
Ashburn 763
Fairfield 506
Dublin 491
Frankfurt am Main 478
Milan 460
Chandler 367
Wilmington 352
New York 306
Woodbridge 305
Houston 256
Santa Clara 241
Dallas 225
Hefei 209
Seattle 203
Ho Chi Minh City 186
Cambridge 183
Beijing 164
Hanoi 160
Princeton 160
Los Angeles 153
Jakarta 149
Jacksonville 111
Chicago 93
Dearborn 86
Seoul 86
Moscow 81
Vienna 76
Lawrence 74
Altamura 72
The Dalles 68
Buffalo 65
Shanghai 63
São Paulo 59
Munich 56
San Diego 55
London 54
Guangzhou 46
Nuremberg 45
Rome 44
Helsinki 40
Boardman 37
Nanjing 35
Andover 33
Rio de Janeiro 32
Tokyo 31
Council Bluffs 30
Haiphong 29
Desio 28
Lappeenranta 28
Dong Ket 27
Salt Lake City 26
Brooklyn 25
Montreal 24
Stockholm 24
Toronto 24
Warsaw 23
Atlanta 22
Lissone 22
Changsha 21
Chennai 21
Denver 21
Falls Church 21
Kent 21
Monza 20
Pune 20
Da Nang 19
Poplar 19
Kocaeli 17
Mumbai 17
Tampa 17
Tianjin 17
Turku 17
Belo Horizonte 16
Ha Long 16
Hebei 16
Jinan 16
Ottawa 16
Phoenix 16
Zhengzhou 16
Johannesburg 15
San Francisco 15
Brasília 14
Brussels 14
Columbus 14
Florence 14
Hangzhou 14
Lachine 14
Tashkent 14
Baghdad 13
Carate Brianza 13
Curitiba 13
Elk Grove Village 13
Mexico City 13
Amsterdam 12
Biên Hòa 12
Bologna 12
Buenos Aires 12
Totale 12.893
Salva come PNG Salva come JPEG
Nome #
Methotrexate inhibits SARS-CoV-2 virus replication "in vitro" 507
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study. 382
A Multidisciplinary Intervention to Tell Children about the Parent's Cancer: Preliminary Results 379
Loss of CDKN2B expression as a potential marker of resistance to CDK4/6 inhibitor in Luminal Breast Cancer cells 347
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20) 324
Comparison of tumor microenvironment in primary and paired metastatic ER+/HER2- breast cancers: results of a pilot study 319
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 318
Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection 317
Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale 312
A second update on mapping the human genetic architecture of COVID-19 304
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 302
TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells 293
Mapping the human genetic architecture of COVID-19 291
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence 283
Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve 273
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity 269
Baseline 18FDG-PET Metabolic Tumour Volume (MTV) as a Potential Predictive Factor of Response to Metronomic Chemotherapy (mCHT) in HR+/HER2- Metastatic Breast Cancer (MBC) Patients (pts). Preliminary Results of the Metro-pet Study 265
Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC) 265
"Why my parent is ill?" A specific, multidisciplinary intervention to enhance comunication to cancer patients' children 257
Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: A genome-wide study replication and meta-analysis 254
Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer 248
The antiangiogenic effect of the metronomic combination of 5-Fluorouracil plus vinorelbine is mediated by FAK/AKT pathway downregulation and apoptosis activation 243
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study 240
Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients 236
Differential Expression of NOTCH-1 and Its Molecular Targets in Response to Metronomic Followed by Conventional Therapy in a Patient with Advanced Triple-Negative Breast Cancer 235
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 228
A Longitudinal Study on Oxaliplatin Induced Peripheral Neuropathy – Incidence and Facts About the “Real Life” Population And Actual Dose 215
Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract 214
A multidisciplinary approach to screen the post-COVID-19 conditions 210
Advanced age and liability to oxaliplatin-induced peripheral neuropathy: post hoc analysis of a prospective study 210
Neurofilament light chain serum levels as a possible paclitaxel-induced peripheral neurotoxicity biomarker: pilot and feasibility study. 210
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective 209
When progressive dysphagia could be related to an “old friend” – a case report 204
Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study 203
Auto-antibodies against type I IFNs in patients with life-threatening COVID-19 200
Incidence, characteristics, and associations of oxaliplatin-induced peripheral neuropathy in colorectal cancer patients: Results of a prospective, multicenter, international study. 198
The significance of dorsal sural nerve recordings in early detecting oxaliplatin-induced peripheral neuropathy. 196
Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients 191
Long-term course of oxaliplatin-induced polyneuropathy: a prospective two-year follow-up study 186
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis 177
Correction: NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer (Breast Cancer Research (2019) 21 (133) DOI: 10.1186/s13058-019-1196-y) 176
Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study 176
Erratum: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9 (31877-31887) DOI: 10.18632/oncotarget.25874) 175
Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation 172
Major issue in chemotherapy-induced peripheral neuropathy (cipn): lack of standardized measurement scales. ciperinoms study: validity and reliability in cipn assessment 172
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study 169
The role for tocilizumab in covid-19 patients: Reflections on monza cohort data 162
Stratified analyses refine association between TLR7 rare variants and severe COVID-19 161
Clinical pattern and associations of oxaliplatin acute neurotoxicity: A prospective study in 170 patients with colorectal cancer 157
Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic 156
Immunomodulatory effects of metronomic vinorelbine (mVRL), with or without metronomic capecitabine (mCAPE), in hormone receptor positive (HR+)/HER2-negative metastatic breast cancer (MBC) patients: final results of the exploratory phase 2 Victor-5 study 154
Molecular and immune biomarkers for cutaneous melanoma: Current status and future prospects 154
Correction: Everolimus (Eve) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study (Oncotarget (2018) 9:77 (34639-34640) DOI: 10.18632/oncotarget.25874) 152
Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success 151
Treatment with gefitinib in elderly patients or patients with poor performance status (PS) affected with non small cell lung carcinoma (NSCLC) 151
Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project 147
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients 146
How to Treat HR+/HER2-Metastatic Breast Cancer Patients after CDK4/6 Inhibitors: An Unfinished Story 143
Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting 143
Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows 142
NSABP FB-7: A phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer 142
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial 142
Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study 141
A possible biomarker for paclitaxel-induced peripheral neurotoxicity: Neurofilament light chain serum levels monitoring 141
Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer 140
Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future? 138
Is There Still a Role for Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies 138
Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project 137
Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE 136
Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial 131
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience 130
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial 129
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 127
Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study 126
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients 123
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study 121
Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19 120
A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy 120
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9) 117
Metronomic chemotherapy 117
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study 117
Targeted therapies for the treatment of breast cancer in the post-trastuzumab era 116
Adjuvant systemic treatment of early breast cancer: the NORA study 115
Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2−) advanced breast cancer patients: New insights beyond clinical trials. The EVA study 110
Low RNA disruption during neoadjuvant chemotherapy predicts pathologic complete response absence in patients with breast cancer 106
Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now? 106
Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: New lessons for clinical practice from the EVA study 104
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study 102
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 102
Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience 102
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 102
Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: Management considerations 100
Biological characteristics and medical treatment of breast cancer in young women-a featured population: results from the NORA study 99
Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers 98
Gene expression profiling in breast cancer: a clinical perspective 96
Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study 95
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study 94
In reply to Kadri Altundag 93
Breast cancer in elderly women: a different reality? Results from the NORA study 92
Treatment of advanced breast cancer with a metronomic schedule of oral vinorelbine: what is the opinion of Italian oncologists? 92
Totale 18.330
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.202
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.202
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.634 0 0 0 0 0 236 223 359 240 210 175 191
2021/20221.198 126 121 150 87 49 90 62 89 58 75 85 206
2022/20232.106 252 550 162 154 121 268 135 140 100 62 87 75
2023/20241.945 89 75 67 93 255 397 354 57 171 56 65 266
2024/20255.336 260 748 412 263 373 265 308 171 561 765 387 823
2025/20265.579 1.320 845 839 1.182 1.282 111 0 0 0 0 0 0
Totale 20.956